Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides

This publication has 9 references indexed in Scilit:

• A pilot trial of G3139, a bcl-2 antisense oligonucleotide,and paclitaxel in patients with chemorefractory small-cell lung cancer
  Annals of Oncology, 2002
• Apoptosis-based therapies
  Nature Reviews Drug Discovery, 2002
• Role of Bcl‐2 family of proteins in malignancy
  Hematological Oncology, 2001
• Inhibition of Potentially Anti-Apoptotic Proteins by Antisense Protein Kinase C-α (Isis 3521) and Antisense bcl-2 (G3139) Phosphorothioate Oligodeoxynucleotides: Relationship to the Decreased Viability of T24 Bladder and PC3 Prostate Cancer Cells
  Molecular Pharmacology, 2001
• Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer
  Seminars in Oncology, 2001
• Chemosensitisation of malignant melanoma by BCL2 antisense therapy
  The Lancet, 2000
• Cellular delivery of antisense oligonucleotides
  European Journal of Pharmaceutics and Biopharmaceutics, 2000
• Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma
  Journal of Clinical Oncology, 2000
• Propagation of Waldenstrom's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model
  Blood, 1993